ArticleJournal of clinical laboratory analysis2026
Plasma Very-Long-Chain Fatty Acids in X-Linked Adrenoleukodystrophy: Diagnostic Insights From a Clinical Laboratory Cohort.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundX-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder caused by pathogenic variants in the ABCD1 gene, leading to accumulation of very long-chain fatty acids (VLCFAs). Plasma VLCFA measurement is central to diagnosis, but its value for prognostic stratification remains uncertain. This study explored the association between biochemical profiles, ABCD1 variants, and clinical phenotypes, and assessed the clinical utility of plasma VLCFA levels.
methodsWe performed a retrospective study of 31 genetically confirmed X-ALD patients from Western Andalusia evaluated between 2005 and 2025. Clinical data, lipid profiles, and VLCFA parameters were analyzed. Patients were stratified by sex, clinical phenotype, genotype, and lipid status. Associations were assessed using Spearman correlation and non-parametric tests, and ROC curves were used to evaluate discrimination for cerebral ALD (CALD).
resultsSymptomatic patients showed higher C26:0 levels and C26:0/C22:0 ratios than asymptomatic individuals, with the highest values in patients with cerebral involvement. VLCFA levels differed across clinically defined groups, although substantial overlap was observed. Truncating ABCD1 variants were associated with higher C26:0 levels and C26:0/C22:0 ratios, but not with cerebral involvement. ROC analysis showed moderate discrimination for CALD (AUC = 0.84). No significant longitudinal changes in VLCFA levels were observed.
conclusionsPlasma VLCFA profiling remains essential for X-ALD diagnosis and shows moderate group-level associations with clinical phenotypes, particularly in cerebral involvement. However, its utility for individual prognostic stratification is limited, supporting the need for complementary biomarkers such as C26:0-LPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.